-
Google banning stem cell-related ads — 3 insights
Google will no longer allow advertisements for unproven or experimental medical procedures in its search results to prevent clinics from misleading patients, The Verge reports. -
4 recent biologics treatments under development
Here are four treatments that are in development in the biologics space: -
Companies partner to develop biologics-based lower back pain treatment
Drugmakers Grünenthal and Mesoblast entered into a partnership to develop a biologics-based treatment for chronic lower back pain. -
NervGen Pharma readies trials for biologic treatment of spinal cord injury, multiple sclerosis
NervGen Pharma is planning its clinical development strategy for its compound, NVG-291, in spinal cord injury and multiple sclerosis patients. -
Lineage Cell Therapeutics earns patent for stem cell-derived spinal cord injury treatment
The U.S. Patent and Trademark Office issued a patent for Lineage Cell Therapeutics' stem cell-derived treatment for spinal cord injury. -
University of Minnesota Medical School receives $945K to advance stem cell therapy
Duchenne UK awarded researchers from Minneapolis-based University of Minnesota Medical School $945,000 to advance their work around a stem cell-based therapy to treat Duchenne muscular dystrophy. -
Opinion: California Institute for Regenerative Medicine wrong to petition for more money
A column by the right-leaning Independent Institute concerned the California Institute for Regenerative Medicine. -
5 stem cell developments in spine, orthopedics
Here are five key developments in stem cell treatments for spine and orthopedics. -
Ohio clinic using biologic treatments
Fairlawn, Ohio-based Crystal Clinic Orthopaedic Center is using biologic therapies to treat anterior cruciate ligament and joint-related injuries. -
Dr. Richard Kim uses stem cells to treat pain
Richard Kim, MD, is using stem cells to help relieve patient pain at his private practice in Saratoga Springs, N.Y. -
Ortho RTi prepares for rotator cuff clinical trial — 4 things to know
Ortho Regenerative Technologies reported a successful pre-investigational drug meeting with the FDA in February and is now preparing for its rotator cuff phase I/II clinical trial. -
Biogennix sets record month for July sales — 3 things to know
In July, orthobiologics company Biogennix hit its best ever month for sales since its formation in 2009. -
IMAC Holdings BioFirma subsidiary earns FDA registered status
Biofirma, a subsidiary of IMAC Holdings, received "registered" status by the FDA. -
Study shows promise for stem cell injections treating spina bifida — 5 things to knows
A study published in Stem Cells Translational Medicine found that an injection of human amniotic fluid stem cells can be used to protect the spinal cord of a fetus from myelomeningocele. -
Surgeon uses Anika's injectable bone repair therapy — 4 insights
John Tierney, DO, used Anika Therapeutics' injectable hyaluronic acid-based bone repair product in a patient. -
Bioventus expands hyaluronic acid product for osteoarthritis into Australia, New Zealand
Bioventus plans to expand Durolane, its hyaluronic acid joint-fluid osteoarthritis injection, into Australia and New Zealand. -
Dr. Penello on what lies ahead for regenerative medicine in orthopedics
Daniel Penello, MD, of Alexander Orthopaedic Associates in St. Petersburg, Fla., is a fellowship-trained orthopedic surgeon who specializes in hand and upper extremity surgery. -
Academic panel to define best practices for outpatient stem cell procedure
A group of orthobiologics experts established a Delphi panel process to set treatment standards for an outpatient stem cell procedure known as bone marrow concentrate. -
PTC Therapeutics signs lease with Bristol-Myers Squibb — 3 insights
PTC Therapeutics is leasing a 185,000-square-foot biologics-focused research space from Bristol-Myers Squibb, BioPharmaReport.com reports. -
A timeline of the California Institute for Regenerative Medicine
The California Institute for Regenerative Medicine has been instrumental in stem cell research since it was first established in 2004, but it faces closure in 2022 if a ballot initiative to get it more funding is unsuccessful.
Page 16 of 34